CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR RFA 0002|
|Brand Name||Bosulif (RFA)|
|Indication||Chronic Myeloid Leukemia|
|Request for Advice Question||RFA Question from the Provincial Advisory Group: Is there evidence of clinical benefit sufficient to extend reimbursement eligibility of bosutinib “for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy” without limiting it further to those “for whom subsequent treatment with imatinib, nilotinib and dasatinib is not clinically appropriate”?|
|Review Status||Notification to Implement Issued|
|Manufacturer||Pfizer Canada Inc.|
|Sponsor||pCODR Provincial Advisory Group|
|Submission Date||April 8, 2019|
|Submission Type||Request for Advice|
|Stakeholder Input Deadline ‡||April 23, 2019|
|pERC Meeting||July 18, 2019|
|pERC RFA Recommendation Issued||August 1, 2019|
|Notification to Implement Issued||August 2, 2019|
‡ Only stakeholders (e.g., submitter/manufacturer(s) of the drug(s) in question, patient groups and registered clinician(s)) who contributed to the original submission in question are eligible to provide input on the Request for Advice Question. Deadlines for Input are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.